• ACAAI Statement on Intranasal and Inhaled Corticosteroids during COVID-19

    As spring allergy season sets in, allergy and asthma sufferers may be concerned that continuing their normal use of inhaled and intranasal corticosteroids may not be advisable during the pandemic. However, it is more important than ever for these patients to keep their symptoms well controlled. The ACAAI has provided the following statement: With the

    Read more →
  • COVID-19 and Nebulized Therapies

    Attention: Midwest Allergy asthma patients Recent data indicates that COVID-19 can persist in droplets in the air for 1 to 2 hours after nebulized therapies.  We are recommending that patients minimize use of nebulized therapies if possible.  If nebulized therapies are necessary, we recommend administering in a location that minimizes exposure to other household members. 

    Read more →